← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

NEOG logoNeogen Corporation(NEOG)Earnings, Financials & Key Ratios

NEOG•NASDAQ
$9.18
$2B mkt cap·Price updated May 6, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryFood, Water and Veterinary Diagnostics
AboutNeogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.Show more
  • Revenue$895M-3.2%
  • EBITDA$135M-32.0%
  • Net Income-$1.09B-11491.6%
  • EPS (Diluted)-5.03-11463.2%
  • Gross Margin47.1%-5.9%
  • EBITDA Margin15.1%-29.7%
  • Operating Margin1.05%-87.4%
  • Net Margin-122.06%-11875.1%
  • ROE-41.88%-13854.6%
  • ROIC0.21%-86.0%
  • Debt/Equity0.44+52.9%
  • Interest Coverage0.13-87.5%
Technical→

NEOG Key Insights

Neogen Corporation (NEOG) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 81 (top 19%)
  • ✓Strong 5Y sales CAGR of 16.4%
  • ✓Trading at only 1.0x book value

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

NEOG Price & Volume

Neogen Corporation (NEOG) stock price & volume — 10-year historical chart

Loading chart...

NEOG Growth Metrics

Neogen Corporation (NEOG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years12.2%
5 Years16.43%
3 Years19.28%
TTM-3.67%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-26.54%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-26.51%

Return on Capital

10 Years8.14%
5 Years3.84%
3 Years1.14%
Last Year0.25%

NEOG Recent Earnings

Neogen Corporation (NEOG) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 9, 2026
EPS
$0.09
Est $0.04
+125.0%
Revenue
$211M
Est $204M
+3.3%
Q1 2026
Jan 8, 2026
EPS
$0.10
Est $0.07
+42.9%
Revenue
$225M
Est $208M
+8.2%
Q4 2025
Oct 9, 2025
EPS
$0.04
Est $0.07
+154.1%
Revenue
$209M
Est $203M
+3.0%
Q3 2025
Jul 29, 2025
EPS
$0.05
Est $0.08
-37.5%
Revenue
$225M
Est $203M
+11.2%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 9, 2026
$0.09vs $0.04+125.0%
$211Mvs $204M+3.3%
Q1 2026Jan 8, 2026
$0.10vs $0.07+42.9%
$225Mvs $208M+8.2%
Q4 2025Oct 9, 2025
$0.04vs $0.07+154.1%
$209Mvs $203M+3.0%
Q3 2025Jul 29, 2025
$0.05vs $0.08-37.5%
$225Mvs $203M+11.2%
Based on last 12 quarters of dataView full earnings history →

NEOG Peer Comparison

Neogen Corporation (NEOG) competitors in Food, Water and Veterinary Diagnostics — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
IDXX logoIDXXIDEXX Laboratories, Inc.Direct Competitor46.12B579.2344.2810.42%24.63%70.87%2.28%0.67
BCAL logoBCALSouthern California BancorpDirect Competitor612.5M19.059.8726.23%27.06%11.36%9.3%0.12
QDEL logoQDELQuidelOrtho CorporationDirect Competitor746.18M10.96-0.66-1.89%-45.57%-56.31%1.46
NVAX logoNVAXNovavax, Inc.Direct Competitor1.54B9.363.6364.69%39.19%
BIO logoBIOBio-Rad Laboratories, Inc.Product Competitor6.99B259.029.290.65%6.52%2.4%5.36%0.21
MESO logoMESOMesoblast LimitedProduct Competitor2.04B15.81-18.82191.39%-5.94%-17.1%0.21
FELE logoFELEFranklin Electric Co., Inc.Product Competitor4.46B100.9831.075.44%6.91%11.44%4.34%0.21
PRAX logoPRAXPraxis Precision Medicines, Inc.Product Competitor7.61B337.95-25.07-100%-58.74%0.00

Compare NEOG vs Peers

Neogen Corporation (NEOG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IDXX

Most directly comparable listed peer for NEOG.

Scale Benchmark

vs TMO

Larger-name benchmark to compare NEOG against a more recognizable public peer.

Peer Set

Compare Top 5

vs IDXX, BCAL, QDEL, NVAX

NEOG Income Statement

Neogen Corporation (NEOG) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemMay'17May'18May'19May'20May'21May'22May'23May'24May'25TTM
Sales/Revenue361.59M397.93M414.19M418.17M468.46M527.16M822.45M924.22M894.66M880.32M
Revenue Growth %12.55%10.05%4.09%0.96%12.03%12.53%56.02%12.37%-3.2%-3.67%
Cost of Goods Sold189.63M211.66M222.27M221.89M253.4M284.15M416.49M461.59M473.29M545.36M
COGS % of Revenue52.44%53.19%53.66%53.06%54.09%53.9%50.64%49.94%52.9%-
Gross Profit
171.97M▲ 0%
186.27M▲ 8.3%
191.92M▲ 3.0%
196.28M▲ 2.3%
215.06M▲ 9.6%
243.01M▲ 13.0%
405.95M▲ 67.1%
462.63M▲ 14.0%
421.38M▼ 8.9%
334.96M▲ 0%
Gross Margin %47.56%46.81%46.34%46.94%45.91%46.1%49.36%50.06%47.1%38.05%
Gross Profit Growth %12.35%8.32%3.03%2.27%9.57%13%67.05%13.96%-8.92%-
Operating Expenses107.02M116.08M123.83M128.76M140.89M184.4M368.44M385.21M411.96M352.2M
OpEx % of Revenue29.6%29.17%29.9%30.79%30.07%34.98%44.8%41.68%46.05%-
Selling, General & Admin96.64M105.22M111.02M114.01M124.64M167.35M342.4M382.76M399.91M411.56M
SG&A % of Revenue26.73%26.44%26.8%27.26%26.61%31.74%41.63%41.41%44.7%-
Research & Development10.38M10.86M12.8M14.75M16.25M17.05M26.04M22.48M21.09M20.47M
R&D % of Revenue2.87%2.73%3.09%3.53%3.47%3.23%3.17%2.43%2.36%-
Other Operating Expenses0000000-20.03M-9.04M-3M
Operating Income
64.94M▲ 0%
70.19M▲ 8.1%
68.09M▼ 3.0%
67.52M▼ 0.8%
74.17M▲ 9.8%
58.62M▼ 21.0%
37.52M▼ 36.0%
77.43M▲ 106.4%
9.42M▼ 87.8%
-17.24M▲ 0%
Operating Margin %17.96%17.64%16.44%16.15%15.83%11.12%4.56%8.38%1.05%-1.96%
Operating Income Growth %15.18%8.08%-2.99%-0.84%9.84%-20.97%-36%106.39%-87.83%-
EBITDA79.64M87.25M85.72M85.92M95.21M82.31M125.89M198.65M135.09M100.38M
EBITDA Margin %22.02%21.93%20.7%20.55%20.32%15.61%15.31%21.49%15.1%11.4%
EBITDA Growth %16.14%9.56%-1.76%0.23%10.81%-13.55%52.94%57.8%-32%-42.1%
D&A (Non-Cash Add-back)14.69M17.06M17.62M18.4M21.04M23.69M88.38M121.23M125.67M117.62M
EBIT66.67M73.47M72.96M72.31M75.27M60.21M33.92M61.37M-1.06B-551.33M
Net Interest Income838K2.04M4.68M5.99M1.61M1.27M-52.8M-67.03M-68.51M-63.3M
Interest Income838K2.04M4.68M5.99M1.69M1.34M3.17M6.36M3.11M2.85M
Interest Expense000078K72K55.96M73.39M71.62M66.16M
Other Income/Expense1.73M3.27M4.87M4.78M1.1M1.59M-59.56M-91.73M-1.14B-600.25M
Pretax Income
66.67M▲ 0%
73.47M▲ 10.2%
72.96M▼ 0.7%
72.31M▼ 0.9%
75.27M▲ 4.1%
60.21M▼ 20.0%
-22.04M▼ 136.6%
-14.3M▲ 35.1%
-1.13B▼ 7821.1%
-617.49M▲ 0%
Pretax Margin %18.44%18.46%17.61%17.29%16.07%11.42%-2.68%-1.55%-126.65%-70.14%
Income Tax22.7M10.25M12.78M12.83M14.39M11.9M828K-4.88M-41.07M-14.75M
Effective Tax Rate %34.05%13.95%17.52%17.74%19.11%19.77%-3.76%34.14%3.62%2.39%
Net Income
43.79M▲ 0%
63.15M▲ 44.2%
60.18M▼ 4.7%
59.48M▼ 1.2%
60.88M▲ 2.4%
48.31M▼ 20.7%
-22.87M▼ 147.3%
-9.42M▲ 58.8%
-1.09B▼ 11491.6%
-602.74M▲ 0%
Net Margin %12.11%15.87%14.53%14.22%13%9.16%-2.78%-1.02%-122.06%-68.47%
Net Income Growth %19.77%44.19%-4.7%-1.16%2.37%-20.65%-147.34%58.81%-11491.59%-26.54%
Net Income (Continuing)43.97M63.22M60.18M59.48M60.88M48.31M-22.87M-9.42M-1.09B-602.74M
Discontinued Operations0000000000
Minority Interest143K000000000
EPS (Diluted)
0.43▲ 0%
0.60▲ 39.5%
0.57▼ 5.0%
0.56▼ 1.8%
0.57▲ 1.8%
0.45▼ 21.1%
-0.12▼ 126.7%
-0.04▲ 63.8%
-5.03▼ 11463.2%
-2.77▲ 0%
EPS Growth %19.44%39.53%-5%-1.75%1.79%-21.05%-126.67%63.75%-11463.22%-26.51%
EPS (Basic)0.430.610.580.570.570.45-0.12-0.04-5.03-
Diluted Shares Outstanding102.33M104.37M104.85M105.72M107.12M108.02M188.88M216.48M216.89M217.41M
Basic Shares Outstanding101.86M103.47M103.78M105.1M106.5M107.68M188.88M216.48M216.89M217.41M
Dividend Payout Ratio----------

NEOG Balance Sheet

Neogen Corporation (NEOG) balance sheet — assets, liabilities & shareholders' equity

Line itemMay'17May'18May'19May'20May'21May'22May'23May'24May'25TTM
Total Current Assets292.96M375.79M449.53M537.41M591.45M626.8M585.93M589.23M576.94M574.58M
Cash & Short-Term Investments143.63M210.81M267.52M343.67M381.09M381.05M245.57M170.94M129M145.34M
Cash Only77.57M83.07M41.69M66.27M75.6M44.47M163.24M170.61M129M145.34M
Short-Term Investments66.07M127.74M225.84M277.4M305.49M336.58M82.33M325K00
Accounts Receivable68.58M79.09M82.58M84.68M91.82M99.67M153.25M173M153.38M132M
Days Sales Outstanding69.2272.5472.7873.9171.5469.0168.0168.3262.5860.53
Inventory73.14M76M85.99M95.05M100.7M122.31M133.81M189.27M190.86M162.77M
Days Inventory Outstanding140.79131.07141.21156.36145.05157.12117.27149.66147.19125.91
Other Current Assets00000053.3M56.02M103.69M134.47M
Total Non-Current Assets235.45M242.22M246.21M259.78M328.74M366.13M3.97B3.96B2.87B2.79B
Property, Plant & Equipment61.75M73.07M74.85M78.67M100.45M110.58M198.75M291.89M356.28M347.46M
Fixed Asset Turnover5.86x5.45x5.53x5.32x4.66x4.77x4.14x3.17x2.51x2.25x
Goodwill104.76M99.56M103.62M110.34M131.48M142.7M2.14B2.14B1.06B1.05B
Intangible Assets68.94M69.59M67.61M66.58M92.32M107.5M1.61B1.51B1.41B1.36B
Long-Term Investments0000000229K00
Other Non-Current Assets-6.77M-3.97M-15.48M647K620K-1.59M7.77M20.2M35.23M-22.99M
Total Assets
528.41M▲ 0%
618.01M▲ 17.0%
695.74M▲ 12.6%
797.18M▲ 14.6%
920.19M▲ 15.4%
992.93M▲ 7.9%
4.55B▲ 358.7%
4.55B▼ 0.1%
3.44B▼ 24.3%
3.36B▲ 0%
Asset Turnover0.68x0.64x0.60x0.52x0.51x0.53x0.18x0.20x0.26x0.25x
Asset Growth %16.98%16.96%12.58%14.58%15.43%7.9%358.69%-0.12%-24.29%-78.9%
Total Current Liabilities36M38.69M38.25M48.49M53.6M77.84M145.47M154.32M174.01M147.05M
Accounts Payable16.24M20.75M19.06M25.65M23.9M34.61M76.67M83.06M79.61M63.04M
Days Payables Outstanding31.2735.7831.342.1934.4344.4667.1965.6861.3948.77
Short-Term Debt00001.28M03.28M2.45M19.3M0
Deferred Revenue (Current)00003.4M5.46M4.62M4.63M5.56M21.02M
Other Current Liabilities14.76M11.87M12.1M0011.12M25.53M26.24M44.8M71.17M
Current Ratio8.14x9.71x11.75x11.08x11.03x8.05x4.03x3.82x3.32x3.32x
Quick Ratio6.11x7.75x9.50x9.12x9.16x6.48x3.11x2.59x2.22x2.22x
Cash Conversion Cycle178.75167.83182.68188.08182.17181.67118.09152.31148.38137.66
Total Non-Current Liabilities20.65M19.15M19.59M23.52M26.22M27.71M1.27B1.25B1.2B1.11B
Long-Term Debt000000885.44M888.39M874.81M792.93M
Capital Lease Obligations000913008.81M10.3M12.86M12.86M
Deferred Tax Liabilities17.05M14.1M15.62M18.13M21.92M17.01M353.43M326.72M280.91M1.13B
Other Non-Current Liabilities3.6M5.04M3.97M5.39M4.3M10.7M27.07M24.96M29.99M158.19M
Total Liabilities56.65M57.83M57.84M72M79.81M105.56M1.42B1.4B1.37B1.26B
Total Debt0001.05M1.29M0897.53M906.24M912.61M792.93M
Net Debt-77.57M-83.07M-41.69M-65.21M-74.32M-44.47M734.29M735.63M783.61M647.59M
Debt / Equity---0.00x0.00x-0.29x0.29x0.44x0.44x
Debt / EBITDA---0.01x0.01x-7.13x4.56x6.76x7.90x
Net Debt / EBITDA-0.97x-0.95x-0.49x-0.76x-0.78x-0.54x5.83x3.70x5.80x5.80x
Interest Coverage----950.88x814.14x0.67x1.05x0.13x-8.33x
Total Equity
471.9M▲ 0%
560.17M▲ 18.7%
637.9M▲ 13.9%
725.18M▲ 13.7%
840.38M▲ 15.9%
887.37M▲ 5.6%
3.13B▲ 253.2%
3.14B▲ 0.3%
2.07B▼ 34.1%
2.1B▲ 0%
Equity Growth %16.77%18.71%13.87%13.68%15.89%5.59%253.2%0.32%-34.12%-103.14%
Book Value per Share4.615.376.086.867.858.2116.5914.529.559.68
Total Shareholders' Equity471.76M560.17M637.9M725.18M840.38M887.37M3.13B3.14B2.07B2.1B
Common Stock8.15M8.28M8.36M16.94M17.2M17.25M34.6M34.66M34.73M34.8M
Retained Earnings295.93M359.07M419.25M478.72M539.6M587.91M565.04M555.62M-536.42M-516.01M
Treasury Stock0000000000
Accumulated OCI-7.2M-9.75M-11.64M-19.71M-11.38M-27.77M-33.25M-30.02M-28.9M-25.61M
Minority Interest143K000000000

NEOG Cash Flow Statement

Neogen Corporation (NEOG) cash flow — operating, investing & free cash flow history

Line itemMay'17May'18May'19May'20May'21May'22May'23May'24May'25TTM
Cash from Operations60.27M69.13M63.84M85.88M81.09M68.04M41.03M35.26M58.24M58.24M
Operating CF Margin %16.67%17.37%15.41%20.54%17.31%12.91%4.99%3.82%6.51%-
Operating CF Growth %70.6%14.69%-7.65%34.52%-5.58%-16.09%-39.7%-14.05%65.17%234.84%
Net Income43.97M63.22M60.18M59.48M60.88M48.31M-22.87M-9.42M-1.09B-602.74M
Depreciation & Amortization14.69M17.06M17.62M18.4M21.04M24.13M90.47M121.23M125.67M123.81M
Stock-Based Compensation5.26M4.91M5.54M6.47M6.44M7.15M10.18M13.77M17.29M17.79M
Deferred Taxes-292K-3M1.2M1.6M-640K-4.7M-19.23M-27.42M-57.78M-45.09M
Other Non-Cash Items-3.92M0000-2.44M6.67M9.8M1.07B526.26M
Working Capital Changes563K-13.05M-20.7M-62K-6.63M-4.42M-24.2M-72.68M-5.93M46.17M
Change in Receivables5.04M-10.23M-4.03M-2.88M-2.6M-7.8M-53.88M-20.1M11.64M17.65M
Change in Inventory-6.97M-2.65M-10.44M-10.01M2.45M-21.07M9.96M-55.95M-16.12M17.99M
Change in Payables-1.69M4.38M-1.46M6.75M-2.22M20.24M18.64M13.75M-402K2.29M
Cash from Investing-62.14M-83.08M-119.15M-88.78M-105.56M-97.23M201.04M-29.31M-99.19M37.68M
Capital Expenditures-14.58M-20.95M-14.66M-24.05M-26.71M-24.43M-65.76M-111.42M-104.59M-84.68M
CapEx % of Revenue4.03%5.26%3.54%5.75%5.7%4.63%8%12.06%11.69%-
Acquisitions-34.03M-468K-6.39M-13.16M-50.77M-38.74M12.55M108K5.08M122.36M
Investments----------
Other Investing0000000000
Cash from Financing25.07M22.84M13.9M29.41M33.54M6.81M-118.08M1.92M-1.6M-101.01M
Debt Issued (Net)000000-100M-420K-321K-100.22M
Equity Issued (Net)1000K1000K1000K1000K1000K1000K1000K1000K1000K2M
Dividends Paid0000000000
Share Repurchases00-3.13M0000000
Other Financing3.92M-423K00-1.09M-1.12M-19.28M-118K-3.52M-4.09M
Net Change in Cash
22.31M▲ 0%
5.51M▼ 75.3%
-41.39M▼ 851.5%
24.58M▲ 159.4%
9.33M▼ 62.0%
-31.13M▼ 433.5%
118.77M▲ 481.5%
7.37M▼ 93.8%
-41.61M▼ 664.5%
5.11M▲ 0%
Free Cash Flow
45.7M▲ 0%
48.19M▲ 5.4%
49.18M▲ 2.1%
61.83M▲ 25.7%
54.38M▼ 12.0%
43.61M▼ 19.8%
-24.73M▼ 156.7%
-76.16M▼ 208.0%
-46.35M▲ 39.1%
17.2M▲ 0%
FCF Margin %12.64%12.11%11.87%14.78%11.61%8.27%-3.01%-8.24%-5.18%1.95%
FCF Growth %116.48%5.45%2.07%25.71%-12.05%-19.8%-156.71%-207.97%39.14%118.44%
FCF per Share0.450.460.470.580.510.40-0.13-0.35-0.21-0.21
FCF Conversion (FCF/Net Income)1.38x1.09x1.06x1.44x1.33x1.41x-1.79x-3.74x-0.05x-0.03x
Interest Paid000078K72K42.62M73.17M68.14M0
Taxes Paid000014.97M17.24M15.47M22.3M26.54M0

NEOG Key Ratios

Neogen Corporation (NEOG) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)10%12.24%10.05%8.73%7.78%5.59%-1.14%-0.3%-41.88%-28.64%
Return on Invested Capital (ROIC)13.11%12.08%9.52%8.06%7.8%5.46%1.19%1.5%0.21%0.21%
Gross Margin47.56%46.81%46.34%46.94%45.91%46.1%49.36%50.06%47.1%38.05%
Net Margin12.11%15.87%14.53%14.22%13%9.16%-2.78%-1.02%-122.06%-68.47%
Debt / Equity---0.00x0.00x-0.29x0.29x0.44x0.44x
Interest Coverage----950.88x814.14x0.67x1.05x0.13x-8.33x
FCF Conversion1.38x1.09x1.06x1.44x1.33x1.41x-1.79x-3.74x-0.05x-0.03x
Revenue Growth12.55%10.05%4.09%0.96%12.03%12.53%56.02%12.37%-3.2%-3.67%

NEOG SEC Filings & Documents

Neogen Corporation (NEOG) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 9, 2026·SEC

Material company update

Mar 30, 2026·SEC

Material company update

Jan 8, 2026·SEC

10-K Annual Reports

2
FY 2025

Jul 30, 2025·SEC

FY 2024

Jul 30, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Apr 9, 2026·SEC

FY 2026

Jan 8, 2026·SEC

FY 2025

Oct 9, 2025·SEC

NEOG Frequently Asked Questions

Neogen Corporation (NEOG) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Neogen Corporation (NEOG) reported $880.3M in revenue for fiscal year 2025. This represents a 6943% increase from $12.5M in 1996.

Neogen Corporation (NEOG) saw revenue decline by 3.2% over the past year.

Neogen Corporation (NEOG) reported a net loss of $602.7M for fiscal year 2025.

Dividend & Returns

Neogen Corporation (NEOG) has a return on equity (ROE) of -41.9%. Negative ROE indicates the company is unprofitable.

Neogen Corporation (NEOG) generated $17.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More NEOG

Neogen Corporation (NEOG) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.